The Company estimates that ANXV has the potential to become a so-called First-In-Class drug for multiple cardiovascular diseases, but focuses on the development of ANXV in the treatment of retinal vein occlusion (RVO) on its own
The Company runs the development programs for ANXV with the aim of minimizing risks and maximizing value before partnership, licensing or sale of the projects. Annexin’s strategy is to conduct clinical efficacy studies at least through phase II in a timely and cost effective manner in patients with retinal vein occlusion (RVO) (described below), where the probability of showing efficacy is assessed to be the highest. Annexin A5 has demonstrated the desired effect in preclinical studies of central RVO (CRVO) which is a vascular disease of the eye, where the blood flow in the eye’s vein is blocked. This can lead to acute or progressively increasing blindness and may affect anyone.
At the same time, the Company intends to maintain and strengthen Annexin’s position by facilitating the future development of ANXV for broader therapeutic areas. Annexin intends to achieve this goal by conducting safety studies and a Phase I clinical trial that may be the basis for the implementation of future clinical trials in several proposed indications.
The Company considers the patent portfolio to be strong, and its scope is crucial for using ANXV in broad therapeutic areas in major markets and major public diseases such as myocardial infarction (acute coronary syndrome, ACS) and peripheral arterial disease in the legs (Peripheral Arterial Occlusive Disease, PAOD). The strategy to maintain a broad patent portfolio aims primarily at increasing the potential for future partners / licensors / buyers to conduct multiple clinical efficacy studies to expand approved indications, so-called “Label expansion”.
In addition to the development program in the above-mentioned indication, RVO, the Company is conducting a research project regarding haemorrhagic fevers, which are acute contagious diseases caused by viruses (such as ebola) and have a major effect on the cardiovascular system. This project is in part financed by grants from Vinnova.